Cagrilintide

Peptoris Labs

Cagrilintide

Sold Out
£85.00

Plan your course

Not sure of the dose? Use the figure from this product's research protocol and choose whether it is per day or per week below.

Dose Frequency Course length

— vial(s) needed at — vial size

Estimate only — based on a steady dose at your chosen frequency and selected vial size. Titration may use less in early weeks. For research use only, not medical advice.

Description

Cagrilintide takes obesity treatment in a different direction by targeting amylin, a hormone co-secreted with insulin from pancreatic beta cells. Amylin naturally promotes satiety, slows gastric emptying, and suppresses glucagon—effects that complement GLP-1 but through distinct pathways. The problem with native amylin is it's short-lived and tends to aggregate. Cagrilintide is an acylated analog designed for once-weekly dosing with improved stability. Alone, it produces meaningful weight loss, but the real excitement is the combination with semaglutide (called CagriSema). Phase 2 trials showed this combination produces weight loss approaching 25%—potentially the most effective obesity treatment ever tested. By hitting both amylin and GLP-1 pathways, you get additive appetite suppression through different brain circuits. Novo Nordisk is racing this through development as the potential successor to Wegovy. Cagrilintide represents the emerging understanding that obesity is a multi-pathway disease requiring multi-pathway treatment.

 

Quickstart Highlights

Cagrilintide is a long‑acting acylated analogue of the pancreatic hormone amylin, designed for once‑weekly subcutaneous administration[1]. It activates central amylin receptors to promote satiety, slow gastric emptying, and reduce food intake[2][3]. In phase 2 and phase 3 trials, cagrilintide produced dose‑dependent weight loss with a predominantly gastrointestinal side‑effect profile[4][5].

    Storage Instructions

    Proper storage preserves peptide integrity and potency.

    • Lyophilized: Store at −20 °C (−4 °F) in dry, dark conditions; minimize moisture exposure.
    • Reconstituted: Refrigerate at 2–8 °C (35.6–46.4 °F); use within 30 days and avoid freeze–thaw cycles.
    • Allow vials to reach room temperature before opening to reduce condensation uptake.

    How It Works

    Cagrilintide is an acylated, long‑acting analogue of amylin—a hormone co‑secreted with insulin from pancreatic beta cells[2][7]. Native amylin promotes satiation, slows gastric emptying, and inhibits postprandial glucagon secretion[8][9]. By acting on central amylin receptors (particularly in the area postrema and hindbrain), cagrilintide reduces appetite and energy intake[3][10]. Lipid modifications extend its half‑life to approximately 160–195 hours, enabling once‑weekly dosing[6][11].

    Potential Benefits & Side Effects

    Observations from phase 2 and phase 3 clinical trials.

    • Weight reduction: In the phase 2 trial, cagrilintide 4.5 mg weekly produced approximately 10.8% body weight loss over 26 weeks versus 3.0% with placebo[4].
    • Combination therapy: When combined with semaglutide 2.4 mg (CagriSema), phase 3 REDEFINE trials showed approximately 20% weight loss at 68 weeks, exceeding results with either agent alone[5][12].
    • Dose‑dependent efficacy: Higher doses (2.4–4.5 mg) demonstrate greater weight loss than lower doses (0.3–1.2 mg)[4].
    • Side effects: Primarily gastrointestinal—nausea, vomiting, diarrhea, and constipation—which are generally mild‑to‑moderate and transient[4][5]. Gradual titration helps minimize these effects.

    References

    Certificate of Analysis

    Every batch of Cagrilintide is independently lab-tested to a minimum of 98% purity. A Certificate of Analysis is available on request — contact us with your order or lot number and we'll send the COA for your specific batch.

    Request a COA

    Research Protocol

    Full dose-by-dose reconstitution & dosing protocol for Cagrilintide.

    View Research Protocol →

    For laboratory and scientific research use only. Not medical advice.

    For laboratory and research use only. Minimum 98% purity. Supplied in sterile, flip-top headspace vials for laboratory use. Not intended for human or animal consumption, medical, diagnostic, therapeutic or veterinary use. These statements have not been evaluated by the MHRA or FDA. The purchaser accepts full responsibility for safe handling, storage and lawful use.